Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 3Q

Diovan expiry and currency impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

3Q Revenues: $13.8 billion (-7%)

3Q Earnings: $3.3 billion (-8%)

YTD Revenues: $41.8 billion (-4%)

YTD Earnings: $9.7 billion (-7%)

Comments: Pharmaceutical sales were $7.8 billion in the quarter (-5%), in part due to the U.S. patent expiration of Diovan. Alcon net sales were $2.5 billion (-1%). Sandoz sales declined 13% to $2.0 billion. Vaccines and Diagnostics sales were down 11% to $582 million, driven by lower flu sales and shipment delays from one of the company’s manufacturing sites. Consumer Health, which includes OTC and Animal Health, declined 22% to $938 million, impacted by the continuing absence of shipments from the Lincoln, NE manufacturing site. Currency had a negative impact of 5% in the quarter and 3% YTD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters